Stockholm
LondonJun 3 – 6PastASCO 2026
ChicagoMay 29 – Jun 2PastEASL Congress 2026
BarcelonaMay 27 – 30PastATS 2026OrlandoMay 15 – 20PastDDW 2026ChicagoMay 2 – 5PastEULAR 2026LondonJun 3 – 6PastASCO 2026ChicagoMay 29 – Jun 2PastEASL Congress 2026BarcelonaMay 27 – 30PastATS 2026OrlandoMay 15 – 20PastDDW 2026ChicagoMay 2 – 5
The Life Science Feed
Podcast
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Normal Flatus Frequency: Up to 25 Episodes Daily Considered Typical
Understanding normal flatus frequency is essential for distinguishing physiological gas from symptoms of gastrointestinal pathology. Up to 25 episodes per day is typical.
Novel Approaches Address Multiple Myeloma Resistance at EHA 2026
Multiple myeloma treatment faces challenges with resistance. New strategies presented at EHA 2026 offer insights into overcoming these hurdles.
AI Enhances Oxygen Therapy Titration, Reduces Hypoxia Duration
Artificial intelligence algorithms are demonstrating efficacy in automating oxygen therapy titration, potentially reducing episodes of hypoxia and hyperoxia.
Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.
ESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice
Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.
PROTEUS Trial: Neoadjuvant Apalutamide Plus ADT in High-Risk Prostate Cancer
The PROTEUS trial investigated neoadjuvant apalutamide plus ADT for high-risk localised prostate cancer, showing improved pathologic complete response rates.
Stay ahead in
Life Science.
CMS Adopts Performance-Based Standards for CRC Biomarker Tests
The Centers for Medicare & Medicaid Services (CMS) has implemented new performance-based standards for colorectal cancer (CRC) biomarker tests, despite ongoing questions regarding the clinical utility of some assays.
Belzutifan Plus Pembrolizumab Approved for Adjuvant RCC
The FDA has approved belzutifan plus pembrolizumab for adjuvant renal cell carcinoma, offering a new option for patients at high risk of recurrence.
ctDNA Predicts Relapse in Early Cancer, but Clinical Action Remains Unclear
Circulating tumour DNA (ctDNA) detection post-surgery predicts relapse in early-stage cancer, but evidence for adjuvant therapy escalation based solely on ctDNA is lacking.
PROTEUS Trial: Neoadjuvant Apalutamide Plus ADT in High-Risk Prostate Cancer
6 min readCAR-T Therapy Versus Bispecific Antibodies
24 minSmall Molecules VS CAR-T In CLL
23 minMoving CAR-T To Earlier Myeloma Lines
24 minCAR-T Masterstroke Or Biological Chaos?
22 minDoctor-Patient Communication Improves Treatment Acceptance in Cancer
6 min read
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
5 min readEASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
6 min readEASL 2026 Forum: Enhancing Patient-Clinician Communication
6 min readEASL 2026: Alcohol Policy Action Needed for Liver Disease
6 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
6 min readMASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
5 min readESC Cardio-Oncology 2026: Key Sessions and Anticipated Focus Areas
The ESC Cardio-Oncology 2026 congress will address cardiotoxicity from cancer therapies, focusing on early detection and management strategies.
Zurich Heart Surgery Scandal: Device Safety Alert Issued
A safety alert has been issued regarding cardiac devices used in Zurich, prompting concerns about patient outcomes and regulatory oversight.
Serum Potassium Concentrations Shape Heart Failure Risk
Optimal serum potassium concentrations in heart failure (HF) are unclear, with new data clarifying the safe range for HFrEF and HFpEF.
Managing Acute Heart Failure And Cardiogenic Shock
25 minSemaglutide For Obese Heart Failure Patients
21 minDiabetes Drugs For Stiff Heart Failure
21 minHow Four Drugs Beat Heart Failure
22 minTricuspid Valve Surgery Benefits Adults with Systemic Right Ventricle
6 min readDual Plane Block May Cut Opioid Use After Bypass Surgery
6 min read
ADA 2026: Key Diabetes Trials to Watch
The upcoming ADA 2026 conference will feature pivotal trials in diabetes management, focusing on novel GLP-1 receptor agonists and SGLT2 inhibitors.
FDA Clears OTC CGM for Non-Insulin-Using Children Aged 2+
The FDA has cleared an over-the-counter continuous glucose monitor for children aged 2 years and older who do not use insulin.
Exercise Declined in Patients with Obesity After Starting a GLP-1
Patients with obesity showed reduced physical activity after initiating GLP-1 receptor agonists, according to a recent analysis.
GLP-1 Receptor Agonists Linked to Elevated Hypotension Risk
5 min readClassic CAH: New Approaches to Glucocorticoid Dosing
7 min readLow Alkaline Phosphatase: Recognizing Clinical Consequences
7 min readAfirma Molecular Testing: Unique Situations and New Prognostic Development
5 min readSevere Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue
6 min readEndocrinologists' Role in Early Thyroid Eye Disease Recognition
6 min read
Preventing 45 Percent Of Dementia Cases
The Lancet Commission 2024 estimates 45% of dementia is preventable. SPRINT-MIND showed 19% MCI reduction from intensive blood pressure control. FINGER showed 25% better cognitive scores with multi-domain lifestyle intervention. ACHIEVE showed 48% slowing in high-risk patients with hearing aids. The evidence is here — we walk through it.
Targeting Tau Inflammation And Alzheimer's Metabolism
Amyloid clearance is only one part of the Alzheimer's story. Why tau remains the closer correlate of cognitive decline, what the TREM2 biology tells us about microglia, what the GLP-1 signal means, and how platform trials are moving toward multi-target combination therapy.
Why New Alzheimer's Drugs Make Brains Bleed?
ARIA — amyloid-related imaging abnormalities — affects up to 24% of patients on anti-amyloid therapy. APOE4 genotyping, MRI monitoring protocols, severity-graded management, and the anticoagulation dilemma: a practical guide to navigating the risk.
The Amyloid Hypothesis, Finally Validated?
39 minCGRP Monoclonal Antibodies for Migraine Linked to Fracture Risk
6 min readReassuring Data for High-Efficacy MS Meds in Pregnancy
6 min readAmyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
7 min readCGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients
5 min readAmyloid Therapies Show Limited Cognitive Benefit in AD
4 min read
